share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GUYER DAVID R

SEC ·  Jul 17 04:28
Summary by Futu AI
On July 12, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a series of transactions involving the company's common stock. Guyer acquired a total of 9,775 shares through the exercise or conversion of derivative securities at prices ranging from $3.26 to $3.50 per share. Subsequently, Guyer sold 11,625 shares on the open market at a price of $10.0641 per share. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals decreased to 1,850 shares. The total market value of the disposed shares amounted to approximately $116,995.16.
On July 12, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a series of transactions involving the company's common stock. Guyer acquired a total of 9,775 shares through the exercise or conversion of derivative securities at prices ranging from $3.26 to $3.50 per share. Subsequently, Guyer sold 11,625 shares on the open market at a price of $10.0641 per share. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals decreased to 1,850 shares. The total market value of the disposed shares amounted to approximately $116,995.16.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated